POOCH: Companion Dog Walking for ICU Survivor Health

Sponsor
University of Missouri, Kansas City (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05820308
Collaborator
SIGMA International Honor Society of Nursing (Other)
30
2
2
5
15
3

Study Details

Study Description

Brief Summary

The goal of this clinical trial is to determine the feasibility and acceptability of a randomized controlled trial comparing a pet dog walking intervention to an attention control education intervention in adult intensive care unit survivors.

The main question[s] it aims to answer are:
  • What is the feasibility of a pet dog-walking intervention compared to an attention control education intervention on depression, anxiety, cortisol, and quality of life for adult ICU survivors.

  • What is the acceptability of a pet dog-walking intervention compared to an attention control education intervention on depression, anxiety, cortisol, and quality of life for adult ICU survivors.

The secondary question[s] it aims to answer are:
  • What are the differences in depression, anxiety, serum cortisol, and quality of life between and within a companion dog walking intervention compared to an attention control education intervention for ICU survivors?
Participants in the intervention group will be asked to:
  • Participate in dog walking with their pet dog at least three times per week, for at least 10 minutes each walk, for 8-weeks.

  • Wear an activity monitor and record their dog walks in a diary.

  • Complete surveys to measure depression, anxiety, and quality of life at the start of the study, after week 4, and after week 8.

  • Have blood drawn to measure cortisol levels at the start of the study, after week 4, and after week 8.

Participants in the control group will be asked to:
  • Read educational materials about their pet dog's health once every week (education materials are provided by the researchers).

  • Wear an activity monitor and record when they read their education materials in a diary.

  • Complete surveys to measure depression, anxiety, and quality of life at the start of the study, after week 4, and after week 8.

  • Have blood drawn to measure cortisol levels at the start of the study, after week 4, and after week 8.

Participants will be assigned to an intervention group or a control group to see if there are differences in depression, anxiety, serum cortisol, and quality of life.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Companion Dog Walking
  • Behavioral: Attention Control Group
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Masking Description:
Participants will be randomly assigned and masked to their group assignment
Primary Purpose:
Other
Official Title:
Feasibility and Acceptability of a Randomized Controlled Trial Comparing a Companion Dog-Walking Intervention to an Attention Control Education Intervention on the Psychological Health of Adult Intensive Care Unit Survivors
Anticipated Study Start Date :
Jun 1, 2023
Anticipated Primary Completion Date :
Nov 1, 2023
Anticipated Study Completion Date :
Nov 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention Group

Companion dog walking

Behavioral: Companion Dog Walking
Participants will be asked to walk their dog three times per week, for a minimum of 30 minutes each day of walking, over an 8-week period.

Active Comparator: Attention Control Group

Educational resources about dog health

Behavioral: Attention Control Group
Participants will be asked to read educational materials on dog health once per week, over an 8-week period.

Outcome Measures

Primary Outcome Measures

  1. Study Feasibility as assessed by recruitment results, attrition rates, intervention fidelity, and missing data points [Feasibility data will be collected and analyzed from the time identifying, screening, and recruiting eligible participants begins to the time the final participant completes the study; no more than 12 months.]

    Data will be collected to answer the following questions: To what extent does the recruitment procedure produce study participants? How many participants met inclusion and exclusion criteria? What are the obstacles to recruitment? What was the attrition rate of participants? To what extent was fidelity of the intervention maintained by participants? To what extent were measurements completed? What was the extent and patterns of missing data?

  2. Study Acceptability as assessed by participant responses to survey questions regarding the amount of time spent in the study, the measurement tools used, the masking procedure, and the intervention. [Acceptability will be assessed post-intervention after participants complete the 8-week study period.]

    Participants will complete an exit survey and will be asked to report on: (1) the acceptability of the time spent in the study and per session, (2) the acceptability of completing the measurement tools, (3) the acceptability of the masking procedure, (4) the acceptability of the intervention, (5) if they intend to continue the intervention after the end of the study, and (6) to report any suggestions for improvement they have.

Secondary Outcome Measures

  1. Change in Depression [Depression will be measured at baseline, half way through the intervention (at the end of week 4), and post intervention (at the end of week 8).]

    The Center for Epidemiologic Studies Depression Scale is a 20-item self-report tool that assesses intensity of depression using a 4-point Likert scale. Lower scores indicate milder levels of depression while higher scores indicate more severe depression (potential score 0-60). Clinically meaningful depression is represented by a score of 16 or greater.

  2. Change in Anxiety [Anxiety will be measured at baseline, half way through the intervention (at the end of week 4), and post intervention (at the end of week 8).]

    The Spielberger State Trait Anxiety Inventory is a 40-item self-report assessment tool using a 4-point Likert scale that assesses both trait and state anxiety. The higher a participant's score (potential score 20-80 on each subscale) the higher the level of anxiety. No/low anxiety = 20-37 points; moderate anxiety= 38-44 points; and high anxiety=45-80 points, with a cut-off point of 39 indicting clinically significant symptoms of anxiety.

  3. Change in Quality of Life as assessed by health related quality of life indicators including physical functioning, physical and emotional limitations, social functioning, bodily pain, general and mental health. [Quality of life will be measured at baseline, half way through the intervention (at the end of week 4), and post intervention (at the end of week 8).]

    The Short Form 36 is a 36-item self-report questionnaire using various ranking questions to measure health related quality of life. The Shot Form 36 examines eight dimensions of health related quality of life (physical functioning, physical and emotional limitations, social functioning, bodily pain, general and mental health). The higher the score (max score =100) the better the health and wellbeing, the lower the score (minimum score=0) the poorer the health and wellbeing.

  4. Change in Serum Cortisol [Serum Cortisol will be measured at baseline, half way through the intervention (at the end of week 4), and post intervention (at the end of week 8).]

    Peripheral venous blood samples will be obtained from participants or analysis at a laboratory.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adult (≥18 years)

  • ICU survivors (spent ≥24 hours in the ICU)

  • Will be discharged directly home from hospital.

  • Able to speak, read, and understand English

  • Physically capable of dog walking

  • Individuals who have symptoms of depression and/or anxiety

  • Individuals who own a companion dog and walk their dog <10 minutes/week

  • Participants scoring ≤ 20 seconds on the TUG Test

Exclusion Criteria:
  • Individuals at high risk for suicide

  • Individuals with severe depression or anxiety

  • Individuals who recently started treatment for depression and/or anxiety

  • Individuals with cognitive impairment

  • Dog walking is deemed unsafe with and for the dog

  • Medical Provider authorization is indicated but not provided

  • Individuals who live outside a 30-mile radius of the hospital.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Penrose Hospital Colorado Springs Colorado United States 80907
2 St. Francis Hospital Colorado Springs Colorado United States 80923

Sponsors and Collaborators

  • University of Missouri, Kansas City
  • SIGMA International Honor Society of Nursing

Investigators

  • Principal Investigator: Lindsey Nelson, MSN, RN, University of Missouri, Kansas City

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Missouri, Kansas City
ClinicalTrials.gov Identifier:
NCT05820308
Other Study ID Numbers:
  • 2094468
First Posted:
Apr 19, 2023
Last Update Posted:
Apr 19, 2023
Last Verified:
Apr 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University of Missouri, Kansas City
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 19, 2023